Abstract: There are disclosed polyhedral superparamagnetic nanoparticles and methods for making and using the nanoparticles. There are also disclosed coated and functionalized forms of the nanoparticles, methods of using nanoparticles and methods of treatment using nanoparticles.

Abstract: The present invention provides a pharmaceutical composition for dialysis wherein the decline of ionized calcium concentration in an acetate-free bicarbonate dialysate comprising no acetic acid and/or sodium acetate is controlled. The present invention further provides a dialysis agent A that comprises electrolytes, citric acid and/or citrate as pH adjuster, and/or glucose, for preparation of bicarbonate dialysates; the agent A characterized by being adjusted by citric acid and/or citrate so as to keep the electrolyte ionized calcium concentration not less than 1 mmol/L in a prepared bicarbonate dialysate. In a specific aspect of the present invention, sodium citrate is used as citrate, and the present invention provides a dialysate obtained from above.

Abstract: The present invention relates to aerosols containing magnetic particles, wherein the aerosols comprise magnetic particles and a pharmaceutical active agent. The invention furthermore relates to the use of such aerosols containing magnetic particles for directed magnetic field-guided transfer of the active agents contained therein in aerosol therapy.

Abstract: The invention discloses the synthesis and manufacturing of a novel core-shell nano-carrier with a drug-containing nanocomposite core surrounding with a single crystalline magnetic iron oxide shell. With a unique core-shell configuration, active agents such as drugs and biomolecules encapsulated in the core with an outer single-crystalline thin iron oxide shell can be perfectly protected from environmental damages and in the meantime, eliminating un-desirable release due to un-controllable diffusion of the active molecules from the nanocapsules during the course of delivery in patient's body, before reaching the disease sites.

Abstract: A pre-compacted materiel comprising one or more calcium-containing compounds and one or more sugar alcohols, wherein the calcium-containing compound having a polycrystallic porous structure. The pre-compacted material is preferably obtained by roller compaction and is suitable for use in the further processing of the pre-compacted material into composition like e.g. tablets.

Abstract: The present invention provides a sprayable gel-type skin/mucosa-adhesive preparation comprising a gel formulation which contains an active pharmaceutical ingredient in a gel base material comprising a skin/mucosa-adhesive agent and an administration system comprising the preparation.

Abstract: The present invention provides a method for preparing chito san solutions to allow regulating the conditions in which the chitosan solution will gel. The present invention also provides methods for using chitosan solutions as compositions and for using chitosan solutions in vitro and in vivo.

Abstract: A method of performing transurethral surgery on the human or animal body. A tissue is cut using a first active cutting electrode and a second neutral electrode, both electrodes being immersed in an electrically conductive aqueous fluid and connected to a power source for applying a voltage and a current between the electrodes. According to the invention, the electrical conductivity of the fluid is at least 25 mS/cm at room temperature. With the invention, complications of surgery can be significantly reduced.

Abstract: The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.

Abstract: The present invention provides a cosmetic composition including oil phase ingredients 40-90% by weight and powder ingredients 10-60% by weight. The oil phase ingredients include volatile oil 5-70 parts by weight and dimethicone/vinyl-dimethicone crosspolymer 0.1-5 parts by weight. The powder ingredients include organic hectorite 0.5-40 parts by weight, methyl methacrylate crosspolymer 0.5-5 parts by weight, and pulverulent body 0.5-50 parts by weight.

Abstract: A medicament package (10,30) comprises a vessel (12,32) adapted to hold a quantity of a liquid vehicle. The vessel (12,32) has an opening formed therein, to which opening is bonded a deformable enclosure (18,38). A medicament container (20) that contains a unit dose of a medicament is received within the enclosure (18,38), such that by deformation of the enclosure (18,38) the container(20) may be dislodged from the enclosure (18,38) into the vessel (12,32), whereby the medicament may escape from the container (20) and mix with the liquid vehicle. The medicament contained within the medicament container (20) is most preferably in admixture with sodium chloride.

Abstract: The present invention provides a continuous process for producing calcium phosphate nanoparticles in a network mixer or static mixer reactor, fed by a calcium solution, a phosphorous solution and an alkaline solution and, optionally, one solvent or dispersing agent. The proposed process enables the micromixing control, which is essential to form nanometric structures, but it is also a determining factor in the crystals purity, crystallinity and morphology. The reactants distribution scheme at the inlet of the reactor and along the reactor, performed continuously or varying in time, is also a crucial factor to programme the pH of the reactant media along the reactor The calcium phosphate nanoparticles suspension that exits the reactor can be submitted to further aging, ultra-sounds, separation, drying, sintering and milling processes.

Abstract: Improved intraocular irrigating solutions are described comprising a cellulose derivative such as hydroxypropylmethylcellulose. In addition, certain solutions of the present invention comprise glutathione and dextrose. The solutions have enhanced viscosities that reduce the risk of damage to intraocular tissues during intraocular surgical procedures by reducing the turbulence of the solutions and dampening the movement of tissue fragments and air bubbles. The solutions preferably also have modified surface tensions that more closely resemble the surface tension of the aqueous humor.

Abstract: An antifreeze gel composition is provided which particularly useful in gel toy to prevent ice formation. The composition includes a water-soluble antifreeze agent such as sorbitol, dextrose; gel was formed by either water-soluble polymers or gums; and salt. The present invention further provides a transparent antifreeze gel and container that is also transparent.

Abstract: The present invention relates to formulations for use as enteric coatings. More particularly, the present invention relates to a formulation comprising a dry blend of food grade ingredients that can be readily dispersed in water. This dispersion exhibits low viscosity and can easily be coated onto solid dosage forms through spraying and the like to provide an enteric coating on the solid dosage form.

Abstract: The invention relates to pigment mixtures comprising at least two components A and B. The inventive pigment mixtures are characterized in that component A is embodied as effect pigments while component B is embodied as coloring agents and fillers. Also disclosed is the use of said pigment mixtures in cosmetic formulations and for coloring food products and pharmaceutical products.

Abstract: One aspect of the present invention relates to stabilized irrigating compositions comprising sodium glycerophosphate and/or calcium glycerophosphate, and a bicarbonate salt. Another aspect of the present invention relates to methods of irrigating ocular tissues during a surgical procedure comprising bathing the intraocular tissues with an irrigating composition comprising sodium glycerophosphate and/or calcium glycerophosphate, and a bicarbonate salt.

Abstract: A method is provided for increasing the permeability of skin or mucosal tissue to topically or transdermally administered pharmacologically or cosmeceutically active agents. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Topically applied formulations and drug delivery devices employing hydroxide-releasing agents as permeation enhancers are provided as well.

Abstract: The present invention is directed to cationic nanoparticles, methods to make them, and the use of compositions containing said nanoparticles in personal care compositions or formulations. The nanoparticles are useful in personal care applications and impart antimicrobial properties to home and personal care products containing them. These cationic nanoparticles also contribute useful conditioning properties to hair-care and skin-care products.

Abstract: The invention relates to porous drug delivery devices and related methods. In an embodiment, the invention includes an active agent delivery system including a reservoir body defining a plurality of interconnected pores, an active agent disposed within the interconnected pores, and a first polymeric layer disposed over the reservoir body. In an embodiment, the invention includes an implantable medical device including a porous substrate defining a plurality of interconnected pores, an active agent disposed within the interconnected pores, and a first polymeric layer disposed over the reservoir body. In an embodiment, the invention includes a method of making an active agent delivery system including forming a porous reservoir body, inserting an active agent within the porous reservoir body, and applying a polymeric layer over the porous reservoir body. Other embodiments are also included herein.

Abstract: The present invention encompasses novel mesoporous compositions comprising vitamin E and alumina, and methods for their synthesis. The mesoporous compositions of the present invention have applications as drug-delivery vehicles.

Abstract: The present invention provides: a carbon nanohorn composite including a carbon nanohorn, a substance encapsulated in the carbon nanohorn, and a polyamine adsorbed by chemical reaction firmly to a surface functional group present on the opening part on the surface of the carbon nanohorn, wherein the release amount and release rate of the encapsulated substance can be controlled using the difference in size, substituent or three-dimensional structure of the polyamine, which is used as a plug; a method of controlling the release of the encapsulated substance; and a process for producing the carbon nanohorn composite. The release amount and release rate of the substance encapsulated in the carbon nanohorn composite is controlled by selecting a polyamine molecule, which plugs the opening part formed in the carbon nanohorn by oxidation, by its size, substituent or three-dimensional structure.

Abstract: The present invention is a powder composition comprising a silicone according to the following formula (1) R1aR2bR3cSio(4-a-b-c)/2??(1) and a powder and/or a coloring agent, a dispersion of powder in an oil in which the powder composition is dispersed, and cosmetics comprising the same, wherein each R1 is, independently, an organic group selected from the group consisting of C1-30 alkyl groups, aryl groups, aralkyl groups, fluorinated alkyl groups, amino-substituted alkyl groups, carboxyl substituted alkyl groups, or polyoxyalkylene groups, R2 is a group derived from polyglycerin, and R3 is a group having an organopolysiloxane moiety.

Abstract: The present invention relates to a process for fabricating a porous coatings with controlled structure in the micro and nano-size domain. In particular, but not exclusively, it relates to a process for fabricating coatings with an anisotropic pore size distribution and to coatings obtained using such coatings. It describes in particular the use of ink-jet method to deposit in a controlled way such coatings. It also relates to porous coatings with controlled structure in the micro and nano-size domain. The coating has a thickness between 10 nanometers and 10 millimeters and its porosity is created in such a way that the pore size distribution is anisotropic. It finally describes objects covered with this coating.

Abstract: Compositions comprising a plurality of functionalized carbon nanotubes and at least one type of payload molecule are provided herein. The compositions are soluble in water and PBS in some embodiments. In certain embodiments, the payload molecules are insoluble in water. Methods are described for making the compositions and administering the compositions. An extended release formulation for paclitaxel utilizing functionalized carbon nanotubes is also described.

Abstract: This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C16. This invention also relates to ophthalmic compositions containing such micellar compositions and methods of using these ophthalmic compositions for the treatment of eye conditions.

Abstract: Novel seed dressing agent formulations comprising of—at least one active agrochemical ingredient for the dressing of seeds, —a dispersion of biologically degradable polyester-polyurethane-polyureas in water whereby the solid content thereof is between 30 and 50 weight %. Said formulation also comprises additives. The invention also relates to a method for the production of a novel seed dressing agent formulation and the utilization thereof for the dressing of seeds.

Abstract: The invention relates to pharmaceutical formulations in liquid form, containing fluoroquinolones and antioxidative sulphur compounds. The formulations are particularly suitable for parenteral uses and are distinguished, inter alia, by good tolerance.

Abstract: The present disclosure generally relates to a formulation. More particularly, the formulation may be applied to skin and/or used in combination with a personal care product to improve absorbance and leakage control of the personal care product, and to promote a more positive feel and comfort through improved skin cleanliness and health.

Abstract: A system for treating obesity, comprises an injectable compound for intramuscular administration in a pyloric sphincter, the injectable compound including a plurality of microspheres and a fluid carrier in which the microspheres are suspended. The system further comprises an injection device having flexibility sufficient to pass through a working channel of an endoscope into the stomach to an injection location adjacent to the pyloric sphincter, the injection device including a tissue piercing tip and a lumen through which the injectable compound may be delivered.

Abstract: An organ regeneration device adapted to be used by placing it into a defective portion of an organ to regenerate the organ is provided. The organ regeneration device has a base body having a shape corresponding to a shape of the defective portion of the organ. The organ regeneration device also has particles carried on the base body, wherein the particles are composed of a different material from that of the base body. The organ regeneration device also has a growth-related substance contained in the organ regeneration device for growth and differentiation of cells around the defective portion. The growth-related substance contains an angiogenesis factor. Further, the growth-related substance contains nucleic acid containing a base sequence coding for amino-acid sequence of a growth factor different from the angiogenesis factor. Furthermore, the nucleic acid is introduced into a host cell.

Abstract: A biodegradable magnesium based metallic material for medical use which is degraded and absorbed in vivo, characterized by comprising a film, which contains magnesium oxide and magnesium hydroxide and is formed on the surface of crystallized magnesium or a magnesium alloy by anodic oxidation. This magnesium based metallic material is capable of exhibiting desired mechanical properties such as strength and ductility at an early stage of implantation without changing the mechanical properties inherent to magnesium or its alloy and also controlling the retention time of the mechanical properties to be short or long in a desired manner.

Abstract: Cosmetic or dermatological preparations which contain modified or unmodified nanocrystalline a-alumina having particle sizes of from 10 to 100 nm and d50 values of from 30 to 60 nm are described.

Abstract: A novel carbon nanotube powder containing carbon nanotubes which have a roll-like structure, also novel carbon nanotubes having a roll-like structure, novel processes for the production of the carbon nanotube powders and of the carbon nanotubes, and their use as an additive or substrate for various applications are described.

Abstract: The present inventions generally relate to compositions and methods for providing agricultural chemicals comprising active ingredients (A.I.s) combined with a top dressing for application to cultivated areas of turfgrass. Specifically, the compositions are in the form of moist formulations for providing top dressings comprising active ingredients. Further, the inventions relate to compositions and methods for delivering active ingredients simultaneously with a top dressing composition to golf course turf.

Abstract: A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41 % of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein.

Abstract: The invention concerns a process for disinfection and/or conservation and/or reduction and/or control of microbial contamination of aqueous dispersions and/or aqueous suspensions of mineral matter, providing satisfactory stability in terms of Brookfield™ viscosity for the said aqueous dispersions and/or suspensions of mineral matter. It also concerns the said aqueous dispersions and/or suspensions thus obtained, together with their uses in the mineral, paper and paint industries. Finally it concerns the end products obtained.

Abstract: A novel method for the preparation of a highly densified and at least partly, preferably fully or almost fully hydrated ceramic for use in the preparation of a pharmaceutical composition notably for controlled-release of one or more therapeutically, prophylactically and/or diagnostically active substance. The method involves a concomitant step of hydrating and densifying a bioresorbable and hydratable ceramic such as calcium sulphate. The invention also relates to compositions comprising such a highly densified ceramic. The pharmaceutical composition is useful for targeted and controlled local prolonged release of active substances, e.g. anti-cancer agents, whereby the spectrum and severity of side effects are minimized due to an optimized local concentration-time profile.

Abstract: A solid pharmaceutical composition for oral administration comprising tegaserod in base or salt form in an amount of up to 10% by weight a bulking agent in an amount of 70 to 90% by weight a disintegrant in an amount of less than 15% by weight a glidant and a lubricant,

Abstract: A therapeutic agent delivery system includes a therapeutic agent, a dendritic salt used as a carrier to effectively deliver the therapeutic agent, and a salt base. The system can include the dendritic salt and the salt base in a ratio of about 1 part dendritic salt to about 8 parts salt base.

Abstract: Disclosed herein are dry film coating compositions comprising of tribasic calcium phosphate as one of the essential ingredient along with other commonly used polymers, plasticizers, excipients like suspending agents, pigments, lubricants, glidents, opacifiers, flavours, sweetener etc. for use in coating of pharmaceutical tablets, nutritional supplements, food products, confectionery, agricultural seeds and the like The invention further discloses method for coating a substrate using the invented coating composition.

Abstract: Transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically but by disparate biochemical pathways. In one embodiment, the transdermal delivery system includes benzyl alcohol and lecithin organogel. The transdermal delivery compositions are used in a variety of topical compositions as a means of transdermally delivering and topically administering different drugs and agents, including compositions promoting collagen biosynthesis, retinoids and skin lighteners, chemical denervation agents such as BOTOX®, anti-fungal agents, anesthetics and non-steroidal anti-inflammatory drugs (NSAIDs). In addition, these topical compositions may be used in combination with non-ablative treatment modalities, such as microdermabrasion, laser-based skin remodeling and radio-frequency-based skin remodeling.

Abstract: A bright pigment including a scaly inorganic base 10 and a silver-based alloy coating 20 that covers the inorganic base 10 and that includes silver and at least one noble metal selected from the group consisting of gold, palladium and platinum, wherein the content of the noble metal is in a range of 0.1 to 2 atomic % when the sum of the atomic % of the silver and the atomic % of the noble metal is 100 atomic %.

Abstract: The present invention relates to a cosmetic composition comprising: a physiologically acceptable medium; monodisperse particles suitable for forming an ordered lattice of monodisperse particles on a substrate on which the composition is applied; and particles that are larger than the monodisperse particles, said larger particles being sufficiently large to avoid preventing the formation of the lattice.

Abstract: The present invention relates to a cosmetic composition comprising: a physiologically-acceptable medium; and monodisperse particles each comprising a core that is insoluble in the medium, with polymer chains that are soluble in the medium extending from the surface of the cores, in particular by grafting, the monodisperse particles being suitable for forming an ordered lattice of monodisperse particles onto a surface to which the composition is applied.

Abstract: The present invention pertains to a sized product, which contains a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent for polyethylene oxide (substance with the appropriate plasticity and binding force) and wherein at least the above-mentioned specific size controlling agent is uniformly dispersed in the above-mentioned polyethylene oxide, a controlled-release pharmaceutical composition containing this sized product, and a method of manufacturing a controlled-release pharmaceutical composition containing this sized product. A controlled-release pharmaceutical composition with good uniformity of content can be presented by using powder particles of polyethylene oxide with powder properties suitable for tableting, which is obtained by uniform dispersion of the specific size controlling agent for polyethylene oxide of the present invention.

Abstract: A composition and method of use of a composition for enhancing the usability of eye cosmetics, including but not limited to mascara and liquid eyeliner. The composition and its formulation contains a liquid enhancer, such that a few drops of the liquid enhancer added to the mascara and/or liquid eyeliner are used to maintain the viscosity, consistency, and smoothness of the cosmetic at the levels of the original, newly provided cosmetic. This enhancement thus allows continued ease of use and longer useful life of the cosmetic material.

Abstract: A pharmaceutically delivery system and method of use therefor are described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.

Abstract: Process for making a solid compound by precipitation, using a high intensity mixing reactor and comprising the steps of (A) introducing a first fluid material containing a first reactant and a second fluid material containing a second reactant into said reactor, in order to obtain a mixed fluid, in order to cause the first reactant to react with the second reactant to form a solid compound by precipitation in the mixed fluid; (B) withdrawing the mixed fluid containing the precipitated solid obtained in step (A) from the reactor, and; (C) optionally separating the precipitated solid compound from at least one fraction of the mixed fluid.

Abstract: A system of equipment allowing addition of solid materials to a pressurized pipeline wherein said solid material is conveyed in such a way as to be readily dissolved by the liquid in said pipeline. The system includes a solid material transfer device that is used to transfer solid material to the point of intake in a pressurized pipeline, without allowing liquid from the process pipeline to access the solid material in the solid material feeder. The system of equipment has been found to be particularly useful in feeding pellets containing resazurin.